Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sativex PK in Advanced Cancer
NCT02432612Phase 1Withdrawn
- Sponsor
- GW Pharmaceuticals
- Start
- Oct 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of cannabidiol in cancer pain, sponsored by GW Pharmaceuticals. Primary endpoints: Pharmacokinetic endpoints of the analyte delta 9-tetrahydrocannabinol (THC), Pharmacokinetic endpoints of the analyte 11-hydroxy-delta 9-tetrahydrocannabinol (11-OH-THC) and 5 more. Planned start Oct 2015; status: withdrawn.
02
Drugs
cannabidiol
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT02432612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02432612.